Benefits of direct-acting antivirals for Hepatitis C

Annals of Internal Medicine

Volumn 167, Issue 11, 2017, Pages 812-813

  Lok, Anna S ^a   Chung, Raymond T ^b   Vargas, Hugo E ^c   Kim, Arthur Y ^b   Naggie, Susanna ^d   Powderly, William G ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MAYO CLINIC   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG;

CLINICAL OUTCOME; COMBINATION DRUG THERAPY; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; SHORT SURVEY; SUSTAINED VIROLOGIC RESPONSE; CHRONIC HEPATITIS C; CLINICAL TRIAL (TOPIC); COMPLICATION; EVIDENCE BASED MEDICINE; LITERATURE; STANDARDS;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HEPATITIS C, CHRONIC; HUMANS; REVIEW LITERATURE AS TOPIC;

EID: 85036625764     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M17-1876     Document Type: Short Survey

References (10)

1. Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017;6:CD012143. [PMID: 28585310] doi:10.1002/14651858.CD012143.pub2
2. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-13. [PMID: 11984517]
3. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies. Ann Intern Med. 2013;158:329-37. [PMID: 23460056] doi:10.7326/ 0003-4819-158-5-201303050-00005
4. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-93. [PMID: 23268517] doi:10.1001/jama.2012.144878
5. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al; ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015; 373:2618-28. [PMID: 26569658] doi:10.1056/NEJMoa1512614
6. Saadoun D, Pol S, Ferfar Y, Alric L, Hezode C, Si Ahmed SN, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology. 2017;153:49-52. [PMID: 28288791] doi:10.1053/j.gastro.2017.03 .006
7. Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128:2527-32. [PMID: 27605512]
8. Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, et al. Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol. 2017;15:421-30. [PMID: 27847279] doi:10.1016/j.cgh .2016.10.037
9. National Academies of Sciences, Engineering, and Medicine. A National Strategy for the Elimination of Hepatitis B and C. Phase Two Report. Washington, DC: National Academies Pr; 2017.
10. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2017. Accessed at www.hcvguidelines .org on 2 July 2017.